CJC-1295 w DAC
CJC-1295 with DAC is a synthetic 30-amino acid GHRH analog with a drug affinity complex that extends its half-life to 6–8 days, studied for sustained growth hormone and IGF-1 elevation.
Free Shipping
over $200
Secure Checkout
256-bit SSL
Description
What is CJC-1295 w DAC?CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid analog of growth hormone-releasing hormone (GHRH) developed by ConjuChem Biotechnologies. It features four amino acid substitutions from native GHRH (1-29) that enhance stability against enzymatic degradation.
The DAC component is a maleimido derivative of lysine that forms a covalent bond with serum albumin after injection, dramatically extending the peptide’s half-life from approximately 30 minutes to 6–8 days. This allows for once-weekly dosing in research protocols.
In clinical studies, a single injection of CJC-1295 DAC increased plasma growth hormone levels by 2- to 10-fold for up to 6 days and IGF-1 levels by 1.5- to 3-fold for 9–11 days. The compound reached Phase II clinical trials but was discontinued.
CJC-1295 is not approved by the FDA for any medical use. All products are sold strictly for laboratory and research purposes only.
Research Applications
Areas of InvestigationSustained GH Release
IGF-1 Elevation
Body Composition
Bone & Collagen Research
Compound Profile
Technical specificationsMolecular Profile
Form
Storage & Stability
Storage (Pre-Reconstitution)
Regulatory & Research Status
COA's (Certificate of Analysis)
Third Party Tested by Freedom DiagnosticsFrequently Asked Questions
Common questions about CJC-1295 w DAC researchFast & SecureUS Shipping
Orders processed within 1 business day, with tracked delivery
Batch-LevelTraceability
Products tied to specific lot numbers and documentation
DedicatedResearch Support
Responsive assistance for documentation and order inquiriers
SecureCheckout
Encrypted transactions and protected customer data